Jupiter Hospitals Expands to Thane with New Hospital Land Purchase

Jupiter Life Line Hospitals Limited is a premier multi-speciality tertiary and quaternary healthcare provider operating under the esteemed “Jupiter” brand in India. Established in 2007, the organisation manages three state-of-the-art hospitals located in Thane, Pune, and Indore, collectively offering an operational bed capacity of 950 as of September 2024.

Acquired Land For ₹400 Crores

Jupiter Life Line Hospitals Ltd. has acquired a prime parcel of land spanning approximately 8,433 square metres in Ghodbundar, Mira Road, Thane district. The forthcoming hospital, designed to cater to underserved regions such as Dahisar, Mira Bhayandar, and the Vasai Virar Municipal areas, underscores the company’s vision of accessible and quality healthcare.

About Jupiter Life Line Hospitals Ltd 

As of January 1, 2025, the company operates an impressive 1,061 beds, maintaining a commendable 67.2% occupancy rate as of September 30, 2024. The proposed facility is anticipated to add a further 300 beds to its capacity, with completion targeted within approximately four years.

This ambitious project entails a capital investment of ₹400 crores, to be primarily funded through internal accruals. The ultimate financing structure will be subject to the Board of Directors’ discretion, adhering to regulatory approvals.

Jupiter Life Line Hospitals Q2 FY25 Results

Jupiter Life Line Hospitals Ltd. reported outstanding financial results for Q2 FY25, with consolidated net profit soaring 52.91% YoY to ₹51.50 crores and revenue from operations rising 22.57% to ₹322.57 crores. 

Profit before tax surged 66.55% to ₹68.9 crores, while EBITDA grew 23.5% to ₹76.6 crores with a robust 19.2% margin. For H1 FY25, total income increased 20.5% to ₹612.8 crores, EBITDA expanded 22.3% to ₹141.9 crores, and PAT rose 9.6% to ₹96.1 crores.

Share Price Performance

At 10:20 AM today, Jupiter Life Line Hospitals Ltd. shares traded at ₹1,530.00 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.